Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL-RT1 trial of zanubrutinib + tislelizumab with or without sonrotoclax for Richter transformation
2023-504653-12-00Phase 2Authorised
- Sponsor
- University of Cologne
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of zanubrutinib, tislelizumab and sonrotoclax in Richter's syndrome (RS), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL) and 1 more (2 arms), sponsored by University of Cologne. Primary endpoint: Overall response rate after induction therapy. Planned start Oct 2023; status: authorised.
02
Drugs
zanubrutinibtislelizumabsonrotoclax
03
Conditions
Richter's syndrome (RS)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)diffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2023-504653-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504653-12-00.